Navigation Links
Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests
Date:5/8/2008

DEERFIELD, Ill., May 8 /PRNewswire-FirstCall/ -- Siemens Healthcare and Laboratory Corporation of America(R) Holdings (LabCorp(R)) today announced that they have entered a non-exclusive agreement to discuss future possibilities to co-develop new clinical diagnostic tests in the areas of companion diagnostics, metabolic syndrome, oncology and diabetes. Under the agreement, initial discussions will focus on developing new tests that could make the biggest impact to patient care.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

Companion diagnostics are tests designed to identify the suitability between patients and a particular drug therapy. The tests can be used in personalized medicine to improve safety and efficacy of therapeutic drugs and in some cases, may help determine optimal dosing for individual patients. Metabolic syndrome is becoming more common and is characterized by a person having multiple risk factors that may include high blood pressure, heart disease, obesity and diabetes, among others. It's estimated that more than 50 million people are affected by this syndrome in the United States alone(1).

Diabetes is a chronic disease currently affecting more than 180 million people worldwide and is likely to more than double by 2030(2). Early detection and treatment of diabetes may enable a patient to better maintain their lifestyle. In addition, the possibility of advancing early detection of cancer is important as it may lead to higher survival rates. One in eight deaths worldwide is due to cancer, and in 2007, there were more than 12 million estimated new cancer cases worldwide(3).

Siemens is a leader in the diagnostic industry with the broadest range of products and services used for diagnosing medical conditions and monitoring patient therapy; LabCorp is a reference laboratory successfully serving more than 220,000 clien
'/>"/>

SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
2. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
3. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
4. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
5. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Hearing health affects a man,s lifestyle, and if he ... professionally engaged, he should address any hearing loss he may ... Better Hearing Institute (BHI) is delivering to men around ... , which leads up to and includes Father,s Day. This ... June 16. To help men address their ...
(Date:5/23/2013)... , May 23, 2013  A recently published clinical ... Houston, Texas , demonstrates that 3D mammography ... cancer detection. The study, "Implementation of ... Study," was led by Stephen L. Rose ... of the American Journal of Roentgenology (AJR). ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... phase II/III clinical trial,anticipated later this year, ... Inc. (CTI) announced the publication of preclinical,studies, ... resulted in minimal or no significant cardiotoxicity, ... studies compared the cardiac side effects of ...
... 2007 - New data from an,investigational study ... Annual Scientific Sessions showed that initial,combination therapy ... in markers of beta cell,function in patients ... function determines the ability of the body ...
Cached Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31
(Date:5/23/2013)... The vast majority of Americans believe it’s possible ... level of physical activity, the healthfulness of their diet ... that control. Those are among the findings of ... & Health Survey. , According to the Survey, 90 ... great deal of control” or “complete control” over their ...
(Date:5/23/2013)... 2013 Click here to read the ... are increasingly seeing their success develop through merger ... according to new research carried out by MaRS ... company has compiled its research into a series of ... the research have shown the general trend that the ...
(Date:5/23/2013)... 23, 2013 Jeanne Ettelson, president of ... its popular and only free OCD support group in ... resource for OCD sufferers, the group is lead by ... disorders. This allows group participants to learn accurate ... Response Prevention. , “Participants in Beyond OCD’s support ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney ... throughout North America. This well known ticket website has ... to help McCartney fans see Sir Paul live in concert. ... she is also offering the customer appreciation code SAVE for ... boomer, she is also a huge McCartney fan and plans ...
(Date:5/23/2013)... News) -- Schools should ensure that kids get ... day to support their health and boost performance ... Although previous studies show 60 minutes of ... development, it,s estimated that only about 50 percent ... according to the report from the Institute of ...
Breaking Medicine News(10 mins):Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... , , Agency says ... SILVER SPRING, Md. , Feb. 5 ... Bayesian statistical methods in the design and analysis of medical ... more efficient patient studies. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , ...
... erosive esophagitis and is the pre-malignant condition for adenocarcinoma ... City University School of Medicine hypothesized that some macroscopic ... a subgroup with a high risk for the development ... January 28, 2010 in the World Journal of ...
... Whitewater Courses ... and challenge participants with hard-to-hear truths about the responsibilities of developers who promote atop ... recreation, designers, engineers and river scientist will take place May 24-27, 2010 in Salida, CO. ... (PRWEB) March 3, 2010 ...
... stable longer , THURSDAY, Feb. 4 (HealthDay News) -- New ... diabetes could benefit by using an artificial pancreas device to ... sleep and help them control their disease. , The findings, ... Lancet , examined use of an artificial pancreas by people ...
... Lean Learning ... need for small-scale reference cards that communicate core Lean concepts in a visually engaging way. ... (PRWEB) February 5, 2010 ... of twelve illustrated cards that teach core Lean concepts with a light and humorous touch. ...
... ... Charlemagne Educational Marketing, LLC launched the release of Swiggs™, the very first live action ... , ... February 5, 2010 -- On February 4, 2010, Charlemagne Educational Marketing, LLC launched the ...
Cached Medicine News:Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 2Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 3Health News:Hard Green Truths - Keynotes Suggest New Value Propositions for River Park Leaders 2Health News:Artificial Pancreas Helps Type 1 Diabetics During Sleep 2Health News:Lean Thinking Pocket Cards Teach Core Concepts -- and Inspire Action 2Health News:First Animated Instructional Oral Sex Video Reaches Mainstream America, Despite the Touchy and Controversial Subject Matter 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: